An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients

Annals of Oncology

Volumn 23, Issue 5, 2012, Pages 1207-1213

  Crea, F ^a   Fornaro, L ^a   Paolicchi, E ^a   Masi, G ^a   Frumento, P ^b   Loupakis, F ^a   Salvatore, L ^a   Cremolini, C ^a   Schirripa, M ^a   Graziano, F ^c   Ronzoni, M ^d   Ricci, V ^d   Farrar, W L ^e   Falcone, A ^a   Danesi, R ^a  

^a UNIVERSITY OF PISA   (Italy)

^b KAROLINSKA INSTITUTE   (Sweden)

^c SAN SALVATORE HOSPITAL   (Italy)

^d SAN RAFFAELE HOSPITAL   (Italy)

^e Laboratory of Cancer Prevention   (United States)

Author keywords

Cancer stem cell; Colorectal cancer; EZH2; FOLFIRI; Polycomb; Polymorphism

Indexed keywords

MESSENGER RNA;

ADULT; AGED; ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; BLOOD SAMPLING; COLORECTAL CANCER; DNA EXTRACTION; EZH2 GENE; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUTATOR GENE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM;

ADENOCARCINOMA; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DNA-BINDING PROTEINS; FEMALE; FLUOROURACIL; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RETROSPECTIVE STUDIES; TRANSCRIPTION FACTORS; TREATMENT OUTCOME;

EID: 84860473474     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr387     Document Type: Article

References (37)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300; (erratum in CA Cancer J Clin 2011; 61: 133-134).
2. Fornaro L, Masi G, Loupakis F et al. Palliative treatment of unresectable metastatic colorectal cancer. Expert Opin Pharmacother 2010; 11: 63-77.
3. Köhne CH, Lenz HJ. Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer. Oncologist 2009; 14: 478-488.
4. Van Cutsem E, Dicato M, Arber N et al. Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009. Ann Oncol 2010; 21 (Suppl 6): vi1-vi10.
5. Kohne CH, Cunningham D, Di CF et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol 2002; 13: 308-317.
6. Walther A, Johnstone E, Swanton C et al. Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer 2009; 9: 489-499.
7. Ricci-Vitiani L, Lombardi DG, Pilozzi E et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007; 445: 111-115.
8. Dallas NA, Xia L, Fan F et al. Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res 2009; 69: 1951-1957.
9. Klarmann GJ, Hurt EM, Mathews LA et al. Invasive prostate cancer cells are tumor initiating cells that have a stem cell-like genomic signature. Clin Exp Metastasis 2009; 26: 433-446.
10. Todaro M, Francipane MG, Medema JP, Stassi G. Colon cancer stem cells: promise of targeted therapy. Gastroenterology 2010; 138: 2151-2162.
11. Mathews LA, Crea F, Farrar WL. Epigenetic gene regulation in stem cells and correlation to cancer. Differentiation 2009; 78: 1-17.
12. Cao Q, Yu J, Dhanasekaran SM et al. Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene 2008; 27: 7274-7284.
13. Tan J, Yang X, Zhuang L et al. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev 2007; 21: 1050-1063.
14. Wang CG, Ye YJ, Yuan J et al. EZH2 and STAT6 expression profiles are correlated with colorectal cancer stage and prognosis. World J Gastroenterol 2010; 16: 2421-2427.
15. Mimori K, Ogawa K, Okamoto M et al. Clinical significance of enhancer of zeste homolog 2 expression in colorectal cancer cases. Eur J Surg Oncol 2005; 31: 376-380.
16. Di Paolo A, Danesi R, Del Tacca M. Pharmacogenetics of neoplastic diseases: new trends. Pharmacol Res 2004; 49: 331-342.
17. Yoon KA, Gil HJ, Han J et al. Genetic polymorphisms in the polycomb group gene EZH2 and the risk of lung cancer. J Thorac Oncol 2010; 5: 10-16.
18. Rhodes DR, Yu J, Shanker K et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004; 6: 1-6.
19. Bracken AP, Dietrich N, Pasini D et al. Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. Genes Dev 2006; 20: 1123-1136.
20. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
21. Giovannetti E, Mey V, Loni L et al. Cytotoxic activity of gemcitabine and correlation with expression profile of drug-related genes in human lymphoid cells. Pharmacol Res 2007; 55: 343-349.
22. Rodriguez S, Gaunt TR, Day IN. Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. Am J Epidemiol 2009; 169: 505-514.
23. Simon JA, Lange CA. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res 2008; 647: 21-29.
24. Lipkin SM, Chao EC, Moreno V et al. Genetic variation in 3-hydroxy-3-methylglutaryl CoA reductase modifies the chemopreventive activity of statins for colorectal cancer. Cancer Prev Res (Phila Pa) 2010; 3: 597-603.
25. Crea F, Giovannetti E, Cortesi F et al. Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines. Mol Cancer Ther 2009; 8(7): 1964-1973.
26. Tsanou E, Peschos D, Batistatou A et al. The E-cadherin adhesion molecule and colorectal cancer. A global literature approach. Anticancer Res 2008; 28: 3815-3826.
27. Kuphal F, Behrens J. E-cadherin modulates Wnt-dependent transcription in colorectal cancer cells but does not alter Wnt-independent gene expression in fibroblasts. Exp Cell Res 2006; 312: 457-467.
28. Chikazawa N, Tanaka H, Tasaka T et al. Inhibition of Wnt signaling pathway decreases chemotherapy-resistant side-population colon cancer cells. Anticancer Res 2010; 30: 2041-2048.
29. Deka J, Wiedemann N, Anderle P et al. Bcl9/Bcl9l are critical for Wnt-mediated regulation of stem cell traits in colon epithelium and adenocarcinomas. Cancer Res 2010; 70(16): 6619-6628.
30. Shen Z, Chen L, Hao F et al. Intron-1 rs3761548 is related to the defective transcription of Foxp3 in psoriasis through abrogating E47/c-Myb binding. J Cell Mol Med 2010; 14: 226-241.
31. Zhang W, Winder T, Ning Y et al. A let-7 microRNA-binding site polymorphism in 3#-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy. Ann Oncol 2011; 22: 104-109.
32. Koong AC, Chauhan V, Romero-Ramirez L. Targeting XBP-1 as a novel anticancer strategy. Cancer Biol Ther 2006; 5: 756-759.
33. Zhang B, Wang M, Yang Y et al. ERp29 is a radiation-responsive gene in IEC-6 cell. J Radiat Res (Tokyo) 2008; 49: 587-596.
34. Matsuzaki Y, Fujisawa J, Yoshida M. Identification of transcriptional activation domain of TREB5, a CREB/ATF family protein that binds to HTLV-1 enhancer. J Biochem 1995; 117: 303-308.
35. Protiva P, Hopkins ME, Baggett S et al. Growth inhibition of colon cancer cells by polyisoprenylated benzophenones is associated with induction of the endoplasmic reticulum response. Int J Cancer 2008; 123: 687-694.
36. Balliet RM, Chen G, Gallagher CJ et al. Characterization of UGTs active against SAHA and association between SAHA glucuronidation activity phenotype with UGT genotype. Cancer Res 2009; 69: 2981-2989.
37. Crea F, Duhagon MA, Farrar WL et al. Pharmacogenomics and cancer stem cells: a changing landscape? Trends Pharmacol Sci 2011; 32: 487-494.